Drugs / GCS-100
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01717248 | Jan → Jun 2013 | chronic kidney disease | La Jolla Pharmaceutical Company | Completed | No outcome recorded |
| Phase 1 | NCT00609817 | May 2008 → Apr 2009 | plasma cell myeloma | La Jolla Pharmaceutical Company | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00776802 | Jul 2008 → Apr 2009 | diffuse large B-cell lymphoma | La Jolla Pharmaceutical Company | Withdrawn | No outcome recorded Stop: Business |
| Phase 25 trials | ||||||
| Phase 2 | NCT02312050 | Mar 2015 → Sep 2016 | diabetic kidney disease | La Jolla Pharmaceutical Company | Unknown | No outcome recorded |
| Phase 2 | NCT02333955 | Jan 2015 → Jul 2016 | chronic kidney disease | La Jolla Pharmaceutical Company | Withdrawn | No outcome recorded |
| Phase 2 | NCT02155673 | Jan 2014 → May 2016 | chronic kidney disease | La Jolla Pharmaceutical Company | Completed | No outcome recorded |
| Phase 2 | NCT01843790 | Jun 2013 → Feb 2014 | chronic kidney disease | La Jolla Pharmaceutical Company | Completed | No outcome recorded |
| Phase 2 | NCT00514696 | Feb 2007 → Apr 2009 | B-cell chronic lymphocytic leukemia | La Jolla Pharmaceutical Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GCS-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00609817 ↗ |
| Action | Inhibit | “GCS-100 is a galectin- 3 antagonist that has been shown to reduce fibrosis pre-clinically.” NCT01843790 ↗ |
| Route | Intravenous | “GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle” NCT00514696 ↗ |